文献速递免疫规划传染病防控与疫情报告

两剂次水痘疫苗接种后突破病例的前瞻性观察及抗体动态变化分析

[Prospective observation of breakthrough cases and analysis of antibody dynamic changes after two doses of varicella].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2022-01-01

在天津市选取1112名接种两剂次水痘疫苗的儿童为试验组,按同一街乡匹配1112名仅接种一剂次儿童为对照组,进行3年前瞻性观察。试验组累计突破率为0.54%(6/1112),低于对照组的3.96%(44/1112,χ²=29.544,P<0.001)。两组各108名儿童第1~3年血清抗体GMC均逐年降低,试验组各年度抗体阳性率均高于对照组(P<0.001)。结论认为两剂次疫苗可显著提升抗体水平和阳性率,但随时间延长仍呈下降趋势,应根据实际情况考虑实行再次加强免疫。

要点

  • 两剂次组累计突破率0.54%(6/1112),低于一剂次组的3.96%(44/1112,P<0.001)。
  • 两剂次组与一剂次组抗体GMC均逐年降低(F=18.291与F=91.383,均P<0.001)。
  • 两剂次组各检测年度抗体阳性率均高于一剂次组(P<0.001)。

核心结论

  • 接种两剂次水痘疫苗能够显著提升接种后的抗体水平和抗体阳性率,但随着时间的延长仍呈下降趋势,应根据实际情况考虑实行再次加强免疫。

研究设计与样本

  • 选取天津市1112名接种两剂次水痘疫苗的儿童作为试验组。
  • 按照同一街乡选择年龄相差1岁之内仅接种过1剂次、且1剂次接种时间与试验组第1剂次接种时间相差小于1个月的儿童作为对照组。
  • 对两组儿童水痘发病情况进行3年的前瞻性观察。
  • 各选取两组中108名儿童同时在第1~3年采集血清进行抗体检测。
  • 采用χ²检验、t检验、方差分析等比较两组突破率以及组间和组内3年间的抗体水平和抗体阳性率。

主要发现

  • 试验组累计突破率为0.54%(6/1112),低于对照组的3.96%(44/1112,χ²=29.544,P<0.001)。
  • 试验组接种水痘疫苗后水痘抗体GMC水平逐年降低(F=18.291,P<0.001),对照组的GMC水平也逐年降低(F=91.383,P<0.001)。
  • 各检测年度试验组和对照组的GMC水平差异有统计学意义(P<0.001)。
  • 试验组3年间的抗体阳性率差异有统计学意义(χ²=11.107,P<0.01),接种第1年与第3年的阳性率差异有统计学意义(P<0.01)。
  • 对照组3年间的阳性率差异无统计学意义(χ²=3.351,P>0.05);各检测年度试验组阳性率均高于对照组(P<0.001)。

临床怎么用

  • 作者认为,应根据实际情况考虑实行再次加强免疫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the breakthrough rate and antibody level of children vaccinated two doses varicella vaccine in Tianjin city, and to compare them with those vaccinated one dose. Methods: A total of 1 112 children who were vaccinated two doses varicella vaccine were selected as the experimental group. According to the same street and township, children who had received only one dose within one year of age difference, and whose first injection time was less than one month from the first dose of varicella vaccine in the experimental group were selected as the control group. A three-year prospective observation was conducted on the incidence of varicella in the two groups. 108 pairs of children in the two groups were selected to collect antivaricella serum in the first to third year. The rate of breakthrough cases, antibody level and antibody positive rate were compared by χ2 test, t-test and variance analysis between and within the two groups in three years. Results: The cumulative breakthrough rate of the experimental group was 0.54%(6/1 112), which was lower than that of the control group 3.96% (44/1 112, χ²=29.544, P<0.001). The GMC level of antibody in the experimental group decreased year by year (F=18.291, P<0.001), and the GMC level in the control group also decreased year by year (F=91.383, P<0.001). There was significant difference in GMC level between the two groups (P<0.001). The difference of antibody positive rate in the experimental group was statistically significant in three years (χ²=11.107, P<0.01), there was significant difference in the positive rate between the first year and third year (P<0.01), there was no significant difference in the positive rate of the control group in three years (χ²=3.351, P>0.05). The positive rate of the experimental group was higher than that of the control group (P<0.001). Conclusion: Two doses varicella vaccine can significantly improve the antibody level and positive rate, but it still shows a downward trend with the extension of time. It is necessary to consider strengthening immunization according to the actual situation. 目的: 分析天津市儿童接种2剂次水痘疫苗后的突破率及抗体水平变化情况,并与仅接种1剂次的儿童进行比较。 方法: 选取1 112名接种2剂次水痘疫苗的儿童作为试验组,按照同一街乡选择年龄相差1岁之内仅接种过1剂次,且1剂次接种时间与试验组第1剂次接种时间相差小于1个月的儿童作为对照组,对两组儿童水痘发病情况进行3年的观察。各选取两组中108名儿童同时在第1~3年采集血清进行抗体检测,采用χ²检验、t检验、方差分析等比较两组突破率以及组间和组内3年间的抗体水平和抗体阳性率。 结果: 试验组累计突破率0.54%(6/1 112),低于对照组的3.96%(44/1 112,χ²=29.544,P<0.001),试验组接种水痘疫苗后水痘抗体GMC水平逐年降低(F=18.291,P<0.001),对照组的GMC水平也逐年降低(F=91.383,P<0.001)。各检测年度试验组和对照组的GMC水平差异有统计学意义(P<0.001)。接种2剂次疫苗的试验组3年间的抗体阳性率差异有统计学意义(χ²=11.107,P<0.01),接种第1年与第3年的阳性率差异有统计学意义(P<0.01),对照组3年间的阳性率差异无统计学意义(χ²=3.351,P>0.05)。各检测年度试验组阳性率均高于对照组(P<0.001)。 结论: 接种2剂次疫苗能够显著提升接种后的抗体水平和抗体阳性率,但随着时间的延长仍呈下降趋势,应根据实际情况考虑实行再次加强免疫。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Dong XC, Li L. [Prospective observation of breakthrough cases and analysis of antibody dynamic changes after two doses of varicella]. Zhonghua Yu Fang Yi Xue Za Zhi. 2022. PMID: 35184437. doi:10.3760/cma.j.cn112150-20210319-00272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。